Valeo Pharma reports Q4 results

admin

Valeo Pharma reports Q4 results

  • Valeo Pharma press release (OTCQB:VPHIF): Q4 net loss of $9.2 million vs $9.3 million in Q4-22.
  • Adjusted EBITDA loss of $4.5 million for Q4-23 vs $2.9 million loss in Q4-22, up 56%.
  • Enerzair and Atectura prescribing physicians reached 2,967 at the end of Q4-23, a 19% growth for the quarter and 161% increase year-over-year.
  • Revenue of $13.1M (+3.1% Y/Y) misses by $0.59M.

SOURCE

Leave a Comment